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Abstract
Background—Self-report measures of medication nonadherence confound the extent of and
reasons for medication nonadherence. Each construct is assessed with a different type of
psychometric model, which dictates how to establish reliability and validity.
Objectives—To evaluate the psychometric properties of a self-report measure of medication
nonadherence that assesses separately the extent of nonadherence and reasons for nonadherence.
Research Design—Cross sectional survey involving the new measure and comparison
measures to establish convergent, discriminant, and concurrent validity. The new measure was re-
administered 2 to 21 days later.
Subjects—202 veterans with treated hypertension were recruited from the Durham Veterans
Affairs Medical Center.
Measures—A new self-report measure assessed the extent of nonadherence and reasons for
nonadherence. Comparison measures included self-reported medication self-efficacy, beliefs about
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medications, impression management, conscientiousness, habit strength, and an existing
nonadherence measure.
Results—Three items assessing the extent of nonadherence produced reliable scores for this
sample, alpha=0.84 (95% CI: 0.80, 0.87). Correlations with comparison measures provided
evidence of convergent and discriminant validity. Correlations with systolic (r=0.27, p<.0001) and
diastolic (r=0.27, p<.0001) blood pressure provided evidence of concurrent validity. Reasons for
nonadherence was assessed with 21 independent items. Intraclass correlations (ICC) were 0.58 for
the extent score and ranged from 0.07 to 0.64 for the reasons.
Conclusions—The dual conceptualization of medication nonadherence allowed a stronger
evaluation of the reliability and validity than was previously possible with measures that
confounded these two constructs. Measurement of self-reported nonadherence consistent with
psychometric principles will enable reliable, valid evaluation of interventions to reduce
nonadherence.
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Medication nonadherence is a significant clinical problem in chronic disease management.
(1, 2) Medication nonadherence is associated with increased healthcare spending,
hospitalization rates, morbidity, and premature mortality.(3)
Obtaining accurate estimates of medication nonadherence is essential to determine where
intervention resources should be directed. There is no ‘gold standard’ for assessing
nonadherence.(4, 5) Pill refills, pill counts, and computerized bottle caps can approximate
how much medication patients are consuming, but only patients can report reasons for not
taking their medications. The self-report method is also appealing because it can be
administered in any setting, is low-cost, and can provide immediate feedback at the point of
care.
Considerable effort has been made to assess self-reported medication nonadherence,
yielding several self-report instruments.(6–9) Although an expert committee recently
identified medication nonadherence as one of the constructs that should be assessed
routinely in electronic health records, it did not recommend an existing measure and
suggested further work was needed.(10) Others have also concluded that existing measures
lack reliability and validity.(11)
Recently, we examined existing self-report measures of medication nonadherence to
determine how measurement could be improved.(12) A key limitation of existing measures
is that they confound two related but distinct nonadherence constructs: the extent to which
doses are missed and the reasons for missing doses. Each construct is assessed by a different
type of psychometric model, which has important measurement implications (Table 1).
Existing self-report measures were not developed with this distinction in mind,
compromising reliability and validity.(12) We developed a self-report measure that assesses
the extent of and reasons for medication nonadherence separately using appropriate
psychometric models. We developed the measure within the context of hypertension (HTN)
because its prevalence is high and nonadherence to antihypertensive medications is
common.(13, 14) We provide initial validation results.
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To inform items assessing the extent of nonadherence, cognitive interviews were conducted
at Duke University with hypertensive patients: 15 with English-speaking Black and White
patients and 15 with Spanish-speaking patients. Participants were asked to discuss how the
following wording choices would affect their estimates of the extent of nonadherence: (1)
percentage versus frequency of doses and (2) recall period of last week versus last month.
Patients found it difficult to quantify behavior in terms of percentages. Patients had various
interpretations of the phrases ‘last week’ and ‘last month,’ suggesting the need to ask about
a specific number of days. Although some patients thought that the ‘last 30 days’ more
accurately reflected long-term adherence, they felt that ‘the last 7 days’ were more easily
and accurately recalled and more sensitive to nonadherence. These findings were used to
generate our initial item pool comprising 5 items asking about medication use over the
previous 7 days.
To generate reasons for nonadherence, we used the 23 situations queried in the Medication
Adherence Self-Efficacy Scale (MASES).(15) Our review of the literature and focus groups
conducted previously(16) did not reveal additional situations. The recall period for these
items was also 7 days.
Design of Validation Study
The study involved two in-person assessments. At Time 1, the newly developed
nonadherence measure and several psychosocial measures were administered. At Time 2 (2
to 21 days later), the newly developed measure was re-administered to provide initial
evidence of stability. Blood pressure (BP) was obtained at both visits to provide evidence of
concurrent validity.
Participants
Participants were recruited from the Durham Veterans Affairs Medical Center (VA), where
Institutional Review Board approval was obtained. Veterans aged > 40 years with a
diagnosis of hypertension were identified from electronic medical records. Inclusion criteria
determined during a screening telephone call were: prescription of at least one
antihypertensive medication, stability of antihypertensive regimen for at least 3 months
prior, and receipt of antihypertensive medications from VA. Exclusion criteria were:
cognitive impairment based on a six-item screener,(17) unable to complete questionnaires
unaided, unable to communicate in English or by telephone, resident in a nursing home or
receiving home health care, or health problem that precludes participation.
Recruitment and Study Procedures
Patients meeting initial inclusion criteria received a recruitment letter and telephone call.
Eligible patients were scheduled for an assessment, which coincided with a scheduled
medical appointment when possible. Reminder letters were mailed prior to the visit and
included instructions not to smoke or consume caffeine or alcohol for at least 60 minutes
prior to the assessment.
At Time 1, the RA conducted the consent process, obtained two BP readings according to
recommended standards,(18) and administered the self-report measures orally. At Time 2,
the RA obtained two BP readings and administered the new nonadherence measure orally.
Participants received $20 for each assessment.
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At Time 1, we collected demographic data, medication names, and dosing instructions in
addition to the measures listed below.
Extent of Nonadherence—Participants rated the extent to which they have missed doses
of their medications over the past 7 days via 5 items with response options: strongly
disagree, strongly agree, neutral, agree, and strongly agree. Higher scores indicate greater
levels of nonadherence.
Reasons for Nonadherence—Participants rated 23 reasons for missed antihypertensive
medications in the past 7 days on 5-point scales anchored by not at all and very much (see
Data, Supplemental Digital Content 1, which includes the extent and reasons items). Higher
scores indicate greater endorsement of each reason for missing dose(s).
Self-Efficacy to Take Antihypertensive Medication—Self-efficacy to take
medication as prescribed was assessed with the 13-item Medication Adherence Self-
Efficacy Scale-Revised (MASES-R),(15) in which participants rated how sure they are that
they can take their medication in certain situations. The internal consistency (estimated
using Cronbach’s coefficient alpha, hereafter referred to as alpha) in our sample was 0.94.
Beliefs about Medicines—The 18-item Beliefs about Medicines Questionnaire (BMQ)
(19) comprises 4 factors: beliefs about the necessity of prescribed medication (Specific-
Necessity; alpha=0.84); beliefs about the danger of dependence and long-term toxicity and
the disruptive effects of medication (Specific-Concerns; alpha=0.78); beliefs that medicines
are harmful, addictive poisons that should not be taken continuously (General-Harm;
alpha=0.74; and beliefs that medicines are overused by doctors (General-Overuse;
alpha=0.80). Higher scores indicate more positive beliefs about medications for the
Necessity factor, and lower scores indicate more positive beliefs about medications on the
others.
Impression Management—Participants completed the 20-item Impression Management
(IM) subscale of the Balanced Inventory of Desirable Responding(20) to assess the tendency
to portray a positive perception to others (alpha=0.72).
Conscientiousness—Participants indicated how well 25 adjectives described them from
1 very inaccurate to 5 very accurate. This scale was designed to assess facets of
conscientiousness. Items were presented in a different random order for each participant to
minimize order effects. Fifteen of the items yielded three facets: orderliness (alpha=0.84),
impulse control (alpha=0.63), and reliability (alpha=0.80). The remaining 10 items not
contributing to a facet in an exploratory factor analysis were not analyzed.
Habit Strength—The habit strength measure was adapted from previous measures (21, 22)
to assess the frequency of medication-taking behavior with one item and situational
consistency with five additional items (physical location, time of day, people present, mood,
and event). Habit strength was calculated as the product of frequency and the mean of the
five situational consistency items.
Blood Pressure—All BP measurements were performed using a digital
sphygmomanometer. Participants sat quietly for 5 minutes. Arm circumference was
measured for the appropriate size cuff, and BP was measured while participants were sitting
in a chair with back rested, both feet on the floor, and arm supported at heart level. A second
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reading was obtained one minute later. The average of the two BP readings was used in
analyses.
Existing Measure of Self-Reported Nonadherence—Participants completed the 8-
item version of the Morisky scale.(7) Two items (2 and 5) assess the extent of nonadherence
over 2 weeks and yesterday, and six items assess reasons for nonadherence: forgetting
(items 1, 4, and 8), feeling worse (item 3), BP in control (item 6), and feeling hassled (item
7). A summary score was calculated.(7) This scale was administered to provide evidence of
convergent validity of the extent measure and to gain initial evidence as to whether
separating extent from reasons improves the relationship with the criterion (BP).
Analysis
The extent of nonadherence is represented by an effect indicator model, in which a person’s
level of medication nonadherence determines their item responses (indicators).(23)
Descriptive statistics were examined for all extent items. Excessive skewness is indicated by
values > 2 and excessive kurtosis by values > 7.(24) Internal consistency and confirmatory
factor analysis (CFA) were conducted to examine the extent to which a single latent variable
contributed to indicators of extent of nonadherence. CFA is an inferential test of the
hypothesis that a single factor accounts for the data. Due to the small item set, a two-factor
model was not tested. To set the metric for the CFA model, all factor loadings were freely
estimated, and the latent factor’s variance was set to 1. Due to the non-normal item
distributions, the response scales were treated as ordinal by specifying categorical variable
type. Incremental model fit was assessed by the Comparative Fit Index (CFI)(25) and
Tucker-Lewis Index (TLI);(26) values >0.95 are generally accepted as good model fit.(27)
Absolute model fit was assessed by Weighted Root Mean Square Residual (WRMR), for
which values <0.90 are generally accepted as good fit.(28) Extent items were considered for
elimination due to excessive missingness, skewness, or kurtosis; insufficient inter-item and
item-total correlations or factor loadings (<0.40);(29) improvement in alpha once an item
was deleted; or redundancy with other items, as indicated by inter-item correlations and
factor loadings much higher than those for other item pairs. The mean of all retained items
was calculated and used in all analyses (see Data, Supplemental Digital Content 2, which
includes the item response theory analyses).
Pearson correlations were computed between extent and comparison measures to provide
information about convergent and discriminant validity. As an a priori guideline, any
correlation >0.50 was considered as evidence of convergent validity and any correlation
<0.30 as evidence of discriminant validity. Because self-efficacy is a proximal determinant
of behavior, we expected a large correlation between extent and medication self-efficacy.
We also expected a large correlation between extent and the Morisky scale to provide
evidence of convergent validity because some Morisky items assess missed doses. We
expected small correlations between extent and the four BMQ subscales, impression
management, conscientiousness, and habit strength to provide evidence of discriminant
validity. Because factors other than nonadherence contribute to elevated BP,(30) we
expected a small to moderate correlation between BP and extent to provide evidence of
predictive validity.
Reasons for nonadherence are represented by a causal indicator model, in which each reason
for nonadherence stands alone as a descriptive indicator for the construct because they
would not necessarily be correlated. (12) Participants indicating any nonadherence (score ≥2
on any extent item) were considered nonadherent,(31) and descriptive statistics for their
reasons items were examined (see Figure, Supplemental Digital Content 3, which includes
the histograms). Reasons items were expected to be skewed and/or kurtotic and not highly
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inter-correlated. We determined a priori that reasons items highly correlated (r >0.60) with
one another would be examined for possible redundancy. Alpha was not calculated because
it is inappropriate for causal indicators.(23)
To examine the test-retest reliability of the nonadherence measures, intraclass correlations
(ICC) were calculated for the extent summary score and each reason using a two-way mixed
model with time as a fixed variable and participants as a random variable.(32) Test-retest
reliability assumes the nonadherence constructs are stable over the two assessment periods
(which ranged from 2 to 21 days). For participants whose reference periods for the
assessment points do not align, there is concern about the stability of the nonadherence
constructs, especially for the reasons scale as reasons for missing a medication may change
over time. Thus, we are not confident that test-retest reliability alone is an accurate indicator
of reliability, nor should it be used alone as the only indicator to retain or remove an item
from the scale.
The target sample size was 200, which provides > 99.5% power to detect the significance of
a correlation of ≥ 0.30 at p = 0.05. The CFA was performed using Mplus (version 6). The
remaining analyses were performed using SAS (version 9; SAS Institute, Cary, NC).
Results
Seven hundred forty recruitment letters were mailed, for which 566 patients were contacted
by telephone. Of those, 100 were ineligible, 210 refused, 6 died before contact, and 250
were scheduled for a Time 1 visit. Forty-eight participants did not show, leaving a Time 1 n
of 202 (36%). Of those, 186 (92%) returned for the Time 2 visit.
Participants were 64 years on average, of mixed racial composition, and primarily male
(Table 2). Nearly three-quarters of participants reported some education beyond high school,
and only 10% reported insufficient income to pay bills.
Extent of Nonadherence
Although the means of all extent items except item 4 were below the scale midpoint, the
distributions were not highly skewed or kurtotic (Table 3). All items except item 4 had
adequate item-total and inter-item correlations. A single factor accounted for the shared
variance among the five extent items, χ2(5)=25.61, p=.0001, CFI=0.99, TLI=0.99,
WRMR=0.60. Although all items had sufficient factor loadings, the item 4 loading was
lower than for the other items. Items 1 and 2 were substantially correlated (r = 0.84),
suggesting redundancy between them. Item 2 was retained in favor of item 1 because its
wording is more specific, and item 4 was eliminated because it measures a related but
different construct (i.e., being late for a dose). Items 2, 3, and 5 were averaged (unweighted)
to create a final summary score, M=1.78 (SD=0.96). These items produced reliable scores,
alpha=0.84 (95% CI: 0.80, 0.87).
As expected, extent was highly correlated with medication self-efficacy (Table 4). Although
correlations between extent and the harm subscale of the BMQ and habit strength were
larger than 0.30, they were not so high as to indicate measurement of a similar construct.
Correlations between extent and the necessity, concerns, and overuse subscales of the BMQ,
impression management, and the three facets of conscientiousness were small in magnitude,
demonstrating discriminant validity. Finally, predictive validity was evidenced by
correlations between extent and BP: for systolic, r(202)=0.27, p <.0001 and for diastolic,
r(202)=0.27, p<.0001.
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Means of the reasons items were well below the scale mid-point, and several distributions
were positively skewed and kurtotic (Table 5). Sixty percent (N = 122) of participants were
considered nonadherent (≥2 on any extent item). The reason endorsed (score ≥2) most was I
forgot. (27%). The least commonly endorsed reasons were feeling too ill to take them (7%)
and going on a long car/plane/bus ride (7%).
As expected, inter-item correlations were, with few exceptions, sufficiently small to suggest
that these items are capturing independent reasons for nonadherence (range −0.01 to 0.81,
average r=0.28). Item 17 (I felt well) was eliminated because it was highly correlated with
and subsumed by item 13 (I felt I did not need them). Item 23 (I was going on a long car/
bus/plane ride) was eliminated because it was highly correlated with and subsumed by item
14 (I was traveling). The result was a list of 21 relatively independent reasons for
nonadherence (range −0.01 to 0.64, average r=0.28).
Relationship with Existing Measure of Nonadherence
To demonstrate the value of treating nonadherence as two related yet distinct constructs, we
examined the structure of the Morisky scale (see Data, Supplemental Digital Content 4,
which includes results of a confirmatory factor analysis). Items 2 and 5, assessing extent of
nonadherence, were only correlated at r = 0.13. Inter-item correlations for the remaining
items, assessing reasons for nonadherence, ranged from −0.10 to 0.55, average r=0.22. Thus,
the Morisky scale did not measure a single underlying construct in this sample. The
correlation between the Morisky total score and extent was r(202) = −0.62, p<0.0001,
providing evidence of convergent validity of our extent measure. The Morisky score was not
correlated with BP: systolic r(202)=−0.03, p=0.68 and diastolic r(202)=−0.02, p=0.74.
Stability of Nonadherence over Time
Time 1 and Time 2 were separated by 2 to 21 days (M=8.32, SD=5.00). ICCs of the
individual extent items ranged from 0.45 to 0.52 (Table 3), and the 3-item total score was
r=0.58, demonstrating moderate short-term stability in the extent of nonadherence. ICCs for
the reasons items varied greatly, ranging from 0.07 to 0.64 (Table 5).
Discussion
Our self-report measure reflects a dual conceptualization of nonadherence.(12) Although
related, the two facets are distinct, requiring different measurement approaches and
evaluation using different psychometric models. Consistent with our conceptualization, the
extent of nonadherence was assessed with three positively correlated items, which produced
reliable scores and correlated as expected with related constructs. Also consistent with our
conceptualization, reasons for nonadherence were assessed with several independent items.
In contrast to the extent items, which are averaged into an overall score, the reasons items
are treated individually in a descriptive manner to inform treatment decisions or to tailor
interventions to increase adherence.
Although short measures are always desirable for research and clinical settings, reliability
and validity must be a priority. Multiple items (in this case, three), rather than a single item,
are needed to assess the extent of nonadherence because the reliability, and therefore
predictive validity, of effective indicators is increased by the use of multiple items. Some
portion of the unreliability in individual items is not shared with other items that vary in
wording and, as such, the composite score, which reflects the commonality across items,
reduces the impact of unreliability on scores.
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The need to assess reasons for nonadherence with many items to provide construct validity
is underscored by the endorsement of individual items by only a small proportion of
participants and by the lack of sizable inter-item correlations. Future research is needed to
determine whether the improved content validity translates to better ability to detect
intervention outcomes or improves clinical practice.
One practical advantage of measuring extent and reasons separately is that the measurement
process can be streamlined: The three extent items can be used to help identify patients with
suboptimal levels of adherence, followed by the reasons items to identify targets of
intervention if necessary. This approach is similar to depression screening, where a positive
2-item Patient Health Questionnaire (PHQ) is followed by a more comprehensive depression
measure or diagnostic interview.(33) Although the response scale for extent items is
continuous, various cutoffs could classify nonadherent individuals, depending on a
researcher’s or clinician’s goals.
Another advantage of measuring the two constructs separately is that longitudinal
assessments may provide a more fine-grained picture of medication taking behavior.
Previous studies have suggested that adherence is episodic.(34) Due to the content of
existing self-report measures, it is difficult to determine whether the extent of nonadherence
or the reasons for nonadherence vary over time. The separate measurement of extent and
reasons in this self-report measure enables independent assessment of both constructs. The
ICCs for extent individual items and total score were moderate to large over 2–21 days,
suggesting that some individuals report a consistent level of nonadherence. In contrast, ICCs
for many reasons items were more modest, indicating that some reasons for nonadherence
are highly variable. More research is needed to elucidate longitudinal patterns of medication
taking behavior, which could inform intervention development and clinical practice.
As scale development is an iterative and ongoing process, we will continue to refine the
measure and build the body of evidence for its reliability and validity. For example, because
the extent items and response scales were not subjected to cognitive interviews, cognitive
interviews should be conducted to improve further the instructions and evaluate different
response scales. More evidence of convergent validity of the extent measure could be
obtained by comparing it to electronic medication monitoring, commonly characterized as a
more objective method.(35)
More evidence of criterion-related validity is needed as well. Although the extent and
Morisky measures were highly correlated, only the extent measure was significantly
associated with BP. Thus, despite some shared variance between the extent and the Morisky
scales, they account for different variance in BP. This pattern of correlations should be
examined in other samples to provide more evidence on the predictive validity of the new
measure. Criterion-related validity may be difficult to establish in hypertension because BP
is highly variable and reflects the influence of other factors.(30, 36) In diseases in which the
outcome is more stable over time, such as LDL treated by statins, a higher correlation might
be expected between extent and the criterion.
Equally important is establishing the psychometric properties of this measure in other
diseases and patient populations. As expected of effect indicator models, the extent measure
should have stable psychometric properties across diseases and populations. The reasons
measure will need to be tailored to characteristics of the disease, patient populations, and
medications used.
In summary, the dual conceptualization of the extent of nonadherence and reasons for
nonadherence provided a framework for the measurement of these constructs. Using this
conceptualization, we developed a preliminary version of a measure to assess these facets
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separately, thereby allowing a stronger evaluation of the reliability and validity than was
possible with existing measures. By improving the measurement of self-reported
nonadherence, we hope to enable better evaluation of interventions to improve patient-
centered outcomes and clinical practice.
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Refer to Web version on PubMed Central for supplementary material.
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Table 1
Using Effect vs. Causal Indicators for Measuring Extent of Nonadherence and Reasons for Nonadherence,
Respectively
Characteristic Extent of nonadherence (effect indicators) Reasons for nonadherence (causal indicators)
Number of items Few Many
Inter-item correlations High, positive No requirement
Reliability Internal consistency (Cronbach’s coefficient alpha), test-
retest (same reference period, stable population)
Test-retest
Validity Content (focus groups, cognitive interviews); Construct
(factor analysis); Convergent and discriminate validity
(correlations with other measures)
Content (focus groups, cognitive interviews)
Scoring Averaged to estimate level of nonadherence Items stand alone as descriptors for reasons for
nonadherence
Use in research Covariate or stratifying variable for treatment efficacy;
outcome in intervention to improve adherence
Provide qualitative information about reasons for
nonadherence; help inform the design or tailoring
of interventions
Generic vs. disease-specific Generic-to be used in any disease population and for any
medication
Both-some reasons are reported across populations,
whereas others are more relevant for a particular
disease population or medication
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Table 2
Demographic Characteristics of Participants (n=202)
Demographic Characteristic
Age, M(SD) 64.1 (11.0)
Male N(%) 173 (86%)
Race
 White 92 (46%)
 Black 99 (50%)
 American Indian 2 (1%)
 Hawaiian or Pacific Islander 1 (<1%)
 Other 4 (2%)
Education
 Grade school/jr. high 4 (2%)
 Some high school 8 (4%)
 High school equivalent or graduate 41 (21%)
 Trade/technical/vocational school 7 (4%)
 Some college credit 48 (25%)
 Associate’s degree 29 (15%)
 Bachelor’s degree 30 (16%)
 Post graduate work or graduate degree 24 (13%)
Financial status
 Difficulty paying bills no matter what 20 (11%)
 Enough to pay bills because cut back on things 17 (9%)
 Enough to pay bills but little spare for special things 49 (26%)
 After paying bills, still have enough for special things 103 (54%)
Note. Within a characteristic, ns may not sum to 202 due to missing data.
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Table 4




Medication self-efficacy −0.42 <.0001
Beliefs about medications-necessity −0.13 .07
Beliefs about medications-concerns 0.25 <.0001
Beliefs about medications-harm 0.31 <.0001
Beliefs about medications-overuse 0.16 .02
Impression management −0.11 .12
Conscientiousness: Orderliness −0.11 .12
Conscientiousness: Impulse control −0.11 .11
Conscientiousness: Reliability −0.15 .04
Habit strength −0.39 <.0001
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